XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-386-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
XBiotech (NASDAQ:XBIT) Frequently Asked Questions
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
How were XBiotech's earnings last quarter?
XBiotech Inc (NASDAQ:XBIT) posted its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View XBiotech's Earnings History.
When is XBiotech's next earnings date?
What price target have analysts set for XBIT?
1 Wall Street analysts have issued twelve-month target prices for XBiotech's stock. Their forecasts range from $13.00 to $13.00. On average, they expect XBiotech's share price to reach $13.00 in the next year. This suggests a possible upside of 35.0% from the stock's current price. View Analyst Price Targets for XBiotech.
What is the consensus analysts' recommendation for XBiotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.
Has XBiotech been receiving favorable news coverage?
Media stories about XBIT stock have trended somewhat negative on Sunday, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. XBiotech earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for XBiotech.
Are investors shorting XBiotech?
XBiotech saw a increase in short interest in August. As of August 31st, there was short interest totalling 3,093,000 shares, an increase of 26.4% from the July 31st total of 2,447,900 shares. Based on an average daily volume of 195,800 shares, the short-interest ratio is currently 15.8 days. Currently, 15.7% of the company's stock are sold short. View XBiotech's Current Options Chain.
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Gossamer Bio (GOSS), G1 Therapeutics (GTHX), Radius Health (RDUS), Theravance Biopharma (TBPH), Opko Health (OPK), Turning Point Therapeutics (TPTX) and BELLUS Health (BLUSF).
What other stocks do shareholders of XBiotech own?
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
- Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
- Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
- Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
- Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board
When did XBiotech IPO?
(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
Who are XBiotech's major shareholders?
XBiotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.31%), Vanguard Group Inc. (2.72%), Sofinnova Investments Inc. (0.92%), Balyasny Asset Management LLC (0.59%), Northern Trust Corp (0.21%) and Bank of New York Mellon Corp (0.15%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.
Which major investors are selling XBiotech stock?
XBIT stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC. Company insiders that have sold XBiotech company stock in the last year include W Thorpe Mckenzie and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.
Which major investors are buying XBiotech stock?
XBIT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Sofinnova Investments Inc., Strs Ohio, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Northern Trust Corp and Citadel Advisors LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.
How do I buy shares of XBiotech?
Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBIT stock can currently be purchased for approximately $9.63.
How big of a company is XBiotech?
XBiotech has a market capitalization of $394.93 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.
What is XBiotech's official website?
How can I contact XBiotech?
XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]
MarketBeat Community Rating for XBiotech (NASDAQ XBIT)
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
